

Mitch Dowsett

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9155216/mitch-dowsett-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158
papers

19,906
citations

57
h-index

141
g-index

167
ext. papers

23,084
ext. citations

8.3
avg, IF

6.34
L-index

#	Paper	IF	Citations
158	Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET. <i>Cancer Research</i> , 2022 , 82, PD2-07-PD2-07	10.1	
157	Abstract PD15-03: Overlapping molecular features (proliferation, immune signatures and TP53 mutations) associated with palbociclib resistance in ER+HER2- primary breast cancer. <i>Cancer Research</i> , 2022 , 82, PD15-03-PD15-03	10.1	
156	Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status. <i>Cancer Research</i> , 2022 , 82, PD14-08-PD14-08	10.1	0
155	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. <i>European Journal of Cancer</i> , 2022 , 164, 52-61	7.5	
154	Code of practice needed for samples donated by trial participants. <i>Lancet Oncology, The</i> , 2022 , 23, e89-e90		2
153	Breast Cancer Prevention Is Better Than Cure. <i>JCO Oncology Practice</i> , 2022 , OP2200002	2.3	
152	UK NEQAS ICC & ISH Ki-67 Data Reveal Differences in Performance of Primary Antibody Clones. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021 , 29, 86-94	1.9	3
151	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 808-819	9.7	95
150	A simple digital image analysis system for automated Ki67 assessment in primary breast cancer. <i>Histopathology</i> , 2021 , 79, 200-209	7.3	3
149	"Real-world" radiomics from multi-vendor MRI: an original retrospective study on the prediction of nodal status and disease survival in breast cancer, as an exemplar to promote discussion of the wider issues. <i>Cancer Imaging</i> , 2021 , 21, 37	5.6	4
148	Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 186, 115-123	4.4	6
147	Calibration of CTS5 in Women With Early Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 338-339	2.2	2
146	Molecular Drivers of Onco DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 126-135	2.2	20
145	Development and validation for research assessment of Oncotype DX, Breast Recurrence Score, EndoPredict and Prosigna. <i>Npj Breast Cancer</i> , 2021 , 7, 15	7.8	6
144	Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 295-305	4.4	1
143	Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. <i>Npj Breast Cancer</i> , 2020 , 6, 21	7.8	24
142	Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1443-1454	21.7	57

141	Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities. <i>Oncogene</i> , 2020 , 39, 4781-4797	9.2	22
140	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. <i>Histopathology</i> , 2019 , 75, 225-235	7.3	37
139	Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 317-326	4.4	1
138	Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 178-189	2.2	80
137	Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. <i>Journal of Clinical Oncology</i> , 2019 , 37, 689-692	2.2	20
136	Combined quantitative measures of ER, PR, HER2, and Ki67 provide more prognostic information than categorical combinations in luminal breast cancer. <i>Modern Pathology</i> , 2019 , 32, 1244-1256	9.8	24
135	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. <i>Anticancer Research</i> , 2019 , 39, 797-802	2.3	
134	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. <i>Modern Pathology</i> , 2019 , 32, 59-69	9.8	51
133	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz049	4.6	4
132	Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. <i>Biomarkers in Cancer</i> , 2019 , 11, 1179299X19851513	7	1
131	Reply to J.A. Sparano et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1842	2.2	
130	The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. <i>Cell Reports</i> , 2019 , 29, 889-903.e10	10.6	17
129	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz050	4.6	6
128	Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients. <i>Breast Cancer Research</i> , 2019 , 22, 2	8.3	6
127	Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors. <i>Clinical Cancer Research</i> , 2019 , 25, 7485-7496	12.9	7
126	Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 42	7.8	9
125	Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 135	8.3	5
124	Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 296-311	19.4	33

123	Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. <i>British Journal of Cancer</i> , 2019 , 120, 247-255	8.7	11
122	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 545-553	13.4	162
121	Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. <i>Journal of Pathology: Clinical Research</i> , 2018 , 4, 262-273	5.3	24
120	The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 4763-4770	12.9	21
119	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1941-1948	2.2	73
118	Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	2
117	Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky005	4.6	5
116	Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. <i>Cancer Prevention Research</i> , 2017 , 10, 171-176	3.2	3
115	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1041-1048	2.2	63
114	11 years Follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <i>Lancet, The</i> , 2017 , 389, 1195-1205	4.0	486
113	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2017 , 19, 16	8.3	52
112	Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women. <i>Cancer Causes and Control</i> , 2017 , 28, 1441-1452	2.8	10
111	Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy. <i>Npj Breast Cancer</i> , 2017 , 3, 47	7.8	3
110	Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. <i>Nature Communications</i> , 2017 , 8, 1865	17.4	79
109	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017 , 377, 1836-1846	59.2	610
108	Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 5043-5048	12.9	16
107	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	131
106	Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 71-8	4.4	7

105	Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. <i>Nature Communications</i> , 2016 , 7, 13294	17.4	23
104	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. <i>Npj Breast Cancer</i> , 2016 , 2, 16014	7.8	86
103	Prognostic value of automated Ki67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. <i>Breast Cancer Research</i> , 2016 , 18, 104	8.3	44
102	Impact of type of full-field digital image on mammographic density assessment and breast cancer risk estimation: a case-control study. <i>Breast Cancer Research</i> , 2016 , 18, 96	8.3	9
101	Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2016 , 18, 58	8.3	71
100	Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2961-8	2.2	420
99	Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. <i>Breast Cancer Research</i> , 2016 , 18, 39	8.3	17
98	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. <i>Endocrine-Related Cancer</i> , 2016 , 23, 77-91	5.7	41
97	miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. <i>Cancer Research</i> , 2016 , 76, 1615-26	10.1	59
96	Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study. <i>Journal of Clinical Pathology</i> , 2016 , 69, 128-35	3.9	11
95	High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. <i>Journal of Pathology: Clinical Research</i> , 2016 , 2, 138-53	5.3	16
94	Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1580-3	2.2	23
93	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2016 , 76, 2301-13	10.1	344
92	Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease. <i>Clinical Cancer Research</i> , 2016 , 22, 2405-16	12.9	36
91	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. <i>JAMA Oncology</i> , 2016 , 2, 1040-7	13.4	48
90	Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039). <i>Clinical Cancer Research</i> , 2015 , 21, 2932-40	12.9	21
89	AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2035-48	6.1	43
88	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. <i>Breast Cancer Research</i> , 2015 , 17, 35	8.3	7

87	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015 , 28, 778-86	9.8	168
86	Reply to E.A. Rakha et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1302-4	2.2	24
85	Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. <i>Science Translational Medicine</i> , 2015 , 7, 302ra133	17.5	679
84	Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints. <i>Breast</i> , 2015 , 24 Suppl 2, S78-83	3.6	16
83	Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. <i>Science Translational Medicine</i> , 2015 , 7, 313ra182	17.5	357
82	Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 1-4	4.4	47
81	Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. <i>Journal of Clinical Oncology</i> , 2015 , 33, 916-22	2.2	152
80	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2763-70	12.9	29
79	Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 327-35	4.4	17
78	Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). <i>Journal of Clinical Oncology</i> , 2014 , 32, 2159-65	2.2	164
77	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. <i>Modern Pathology</i> , 2014 , 27, 4-18	9.8	191
76	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014 , 16, R51	8.3	12
75	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. <i>Lancet Oncology</i> , 2014 , 15, 1460-1468	21.7	51
74	Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response. <i>Clinical Cancer Research</i> , 2014 , 20, 2485-94 ^{12.9}	12.9	34
73	Reply to R. Bhargava et al and K. Lambein et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1857-9	2.2	3
72	Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 3962-73	12.9	14
71	Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. <i>European Journal of Cancer</i> , 2014 , 50, 1055-64	7.5	29
70	Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. <i>Lancet Oncology</i> , 2013 , 14, 1067-1076	21.7	266

69	An international Ki67 reproducibility study. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1897-906	9.7	398
68	Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2783-90	2.2	462
67	Sex hormones and breast cancer risk and prognosis. <i>Breast</i> , 2013 , 22 Suppl 2, S38-43	3.6	69
66	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3997-4013	2.2	2593
65	Biomarkers for the clinical management of breast cancer: international perspective. <i>International Journal of Cancer</i> , 2013 , 133, 1-13	7.5	118
64	Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 157-65	4.4	32
63	Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. <i>Clinical Cancer Research</i> , 2013 , 19, 2775-86	12.9	96
62	GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. <i>Cancer Research</i> , 2013 , 73, 3783-95	10.1	74
61	The role of caveolin-1 in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 1-15	4.4	51
60	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. <i>Breast Cancer Research</i> , 2012 , 14, R57	8.3	65
59	Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 1191-8	4.4	32
58	Predictive algorithms for adjuvant therapy: TransATAC. <i>Steroids</i> , 2011 , 76, 777-80	2.8	31
57	Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4273-8	2.2	549
56	Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1656-64	9.7	1156
55	ER-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. <i>Cancer Discovery</i> , 2011 , 1, 338-51	24.4	242
54	Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4365-72	2.2	98
53	Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 120-3	4.8	60
52	Comparative validation of the SP6 antibody to Ki67 in breast cancer. <i>Journal of Clinical Pathology</i> , 2010 , 63, 800-4	3.9	51

51	Reply to M. Rosman et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e648-e648	2.2	1
50	Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1161-7 ²	2.2	88
49	Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1829-34	2.2	547
48	Reply to B. Seruga et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e348-e348	2.2	
47	Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. <i>Journal of Clinical Oncology</i> , 2010 , 28, 509-18	2.2	615
46	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2010 , 11, 1135-41	21.7	671
45	Predictive and prognostic factors. <i>Breast Cancer Research</i> , 2010 , 12 Suppl 4, S2	8.3	3
44	Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 829-36	4.4	32
43	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2010 , 134, 907-22	5	391
42	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). <i>Archives of Pathology and Laboratory Medicine</i> , 2010 , 134, e48-72	5	729
41	Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2962-9	2.2	141
40	The potential of new technologies/approaches. Introduction to Sessions 3 and 4. <i>Breast Cancer Research</i> , 2009 , 11 Suppl 3, S9	8.3	
39	Who would have thought a single Ki67 measurement would predict long-term outcome?. <i>Breast Cancer Research</i> , 2009 , 11 Suppl 3, S15	8.3	12
38	Optimizing the implementation of future treatment using surrogate end-points. <i>Breast Cancer Research</i> , 2008 , 10 Suppl 4, S26	8.3	5
37	Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 8019-26	12.9	189
36	Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1059-65	2.2	360
35	Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1380-8	9.7	469
34	Standardization of HER2 testing: results of an international proficiency-testing ring study. <i>Modern Pathology</i> , 2007 , 20, 584-91	9.8	109

33	Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 167-70	9.7	531
32	HER2 testing in the UK: consensus from a national consultation. <i>Journal of Clinical Pathology</i> , 2007 , 60, 685-9	3.9	28
31	Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 103, 99-109	5.1	56
30	International Web-based consultation on priorities for translational breast cancer research. <i>Breast Cancer Research</i> , 2007 , 9, R81	8.3	76
29	Comparison of methods to measure low serum estradiol levels in postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 3791-7	5.6	150
28	Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 1024s-1030s	12.9	92
27	Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3019-25	2.2	151
26	Mechanisms of resistance to aromatase inhibitors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 95, 167-72	5.1	50
25	Deficits in plasma oestradiol measurement in studies and management of breast cancer. <i>Breast Cancer Research</i> , 2005 , 7, 1-4	8.3	56
24	The biology of steroid hormones and endocrine treatment of breast cancer. <i>Breast</i> , 2005 , 14, 452-7	3.6	37
23	Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. <i>Breast Cancer Research and Treatment</i> , 2005 , 93 Suppl 1, S11-8	4.4	57
22	Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2477-92	2.2	228
21	Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7512-7	2.2	214
20	Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5108-16	2.2	599
19	Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. <i>Clinical Cancer Research</i> , 2005 , 11, 951s-8s	12.9	181
18	Translational research and the changing face of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2004 , 87 Suppl 1, S1-2	4.4	19
17	Biomarker investigations from the ATAC trial: the role of TA01. <i>Breast Cancer Research and Treatment</i> , 2004 , 87 Suppl 1, S11-8	4.4	11
16	Designing the future shape of breast cancer diagnosis, prognosis and treatment. <i>Breast Cancer Research and Treatment</i> , 2004 , 87 Suppl 1, S27-9	4.4	4

15	Efforts to link biological and clinical breast cancer research. <i>Breast</i> , 2003 , 12, 442-6	3.6	2
14	Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. <i>Seminars in Oncology</i> , 2003 , 30, 58-69	5.5	43
13	New biology of the oestrogen receptor. <i>Lancet, The</i> , 2003 , 362, 260-2	4.0	12
12	Aromatase inhibitors in breast cancer. <i>New England Journal of Medicine</i> , 2003 , 348, 2431-42	59.2	704
11	Preoperative models to evaluate endocrine strategies for breast cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 502S-10S	12.9	18
10	Breast cancer: aromatase inhibitors take on tamoxifen. <i>Nature Medicine</i> , 2002 , 8, 1341-4	50.5	28
9	Measurement of markers for breast cancer in a model system using laser scanning cytometry. <i>Cytometry</i> , 2000 , 41, 166-71		15
8	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. <i>Cancer</i> , 1999 , 85, 1996-2000	6.4	15
7	Clinical pharmacology of selective estrogen receptor modulators. <i>Drugs and Aging</i> , 1999 , 14, 323-36	4.7	23
6	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma 1999 , 85, 1996		1
5	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. <i>Cancer</i> , 1999 , 85, 1996-2000	6.4	59
4	Pharmacological and clinical profile of anastrozole. <i>Breast Cancer Research and Treatment</i> , 1998 , 49 Suppl 1, S53-7; discussion S73-7	4.4	9
3	Effects of 4-hydroxyandrost-4-ene-3,17-dione and its metabolites on 5 alpha-reductase activity and the androgen receptor. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1992 , 6, 141-7		8
2	Comparison of aromatase activity in human prostatic, testicular and placental tissues. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1991 , 4, 307-13		6
1	Unmasking the tissue microecology of ductal carcinoma in situ with deep learning		2